Drug Type Small molecule drug |
Synonyms OTS 167, OTS 167PO, OTSSP167 |
Target |
Mechanism MELK inhibitors(Maternal embryonic leucine zipper kinase inhibitors), NLK inhibitors(nemo like kinase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Lymphoblastic Leukemia | Phase 2 | US | 01 Apr 2016 | |
Acute Myeloid Leukemia | Phase 2 | US | 01 Apr 2016 | |
Myelodysplastic Syndromes | Phase 2 | US | 01 Apr 2016 | |
Philadelphia chromosome positive chronic myelogenous leukemia | Phase 2 | US | 01 Apr 2016 | |
Advanced breast cancer | Phase 1 | US | 29 May 2017 | |
Metastatic breast cancer | Phase 1 | US | 29 May 2017 | |
Triple Negative Breast Cancer | Phase 1 | US | 29 May 2017 | |
Anemia, Diamond-Blackfan | Preclinical | US | 10 Dec 2023 | |
Ovarian Cancer | Preclinical | JP | 25 Aug 2020 | |
Multiple Myeloma | Preclinical | JP | 26 Nov 2016 |